{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:20:08Z","timestamp":1794550808364,"version":"4.9.1"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2022,9,19]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Age-related macular degeneration (AMD) represents a leading cause of blindness worldwide. Neovascular AMD (nAMD) is a subtype of AMD most frequently treated with intravitreal anti-vascular endothelial growth factor (aVEGF) injections, which has allowed for patients to maintain vision that would have otherwise been lost. However, the need for frequent intravitreal injections for optimal results poses a risk for undertreatment in nAMD patients due to the high treatment burden associated with current aVEGF therapy. Many novel agents and pathways are being explored and targeted for less burdensome treatment options, one of which is the ranibizumab port delivery system (PDS). The PDS is a surgically implanted, refillable device that allows for the sustained release of ranibizumab, a widely used aVEGF agent, into the vitreous cavity. Positive results non-inferior to monthly ranibizumab injections in both phase II and phase III clinical trials allowed for FDA approval of the device with refill intervals of 6 months, which represents the longest approved treatment interval to date for nAMD therapy. This article reviews the need for a durable nAMD treatment option in real-world practice, the clinical trial and extension study data for the PDS, the risk of adverse events and safety profile of the PDS and the potential clinical role of the PDS in answering the real-world needs of nAMD treatment. In addition, other pipeline sustained-treatment modalities are discussed in the context of ongoing clinical trials.<\/jats:p>","DOI":"10.1136\/bmjophth-2022-001104","type":"journal-article","created":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T12:32:00Z","timestamp":1664195520000},"page":"e001104","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Ranibizumab port delivery system: a clinical perspective"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct03683251","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03683251","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03953079","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04747197","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-0668","authenticated-orcid":false,"given":"David A","family":"Eichenbaum","sequence":"first","affiliation":[{"name":"Retina Vitreous Associates of Florida, Saint Petersburg, Florida, USA"},{"name":"Morsani College of Medicine at the Univeristy of South Florida, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahim","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine at the Univeristy of South Florida, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Hiya","sequence":"additional","affiliation":[{"name":"Bascom Palmer Eye Institute Mary and Edward Norton Library of Ophthalmology, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"2025090109453561000_7.1.e001104.1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(13)70145-1"},{"key":"2025090109453561000_7.1.e001104.2","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2025090109453561000_7.1.e001104.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2012.10.018","article-title":"Age-related macular degeneration revisited--piecing the puzzle: the LXIX Edward Jackson memorial lecture","volume":"155","author":"Miller","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025090109453561000_7.1.e001104.5","doi-asserted-by":"publisher","DOI":"10.1159\/000517520"},{"key":"2025090109453561000_7.1.e001104.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317434"},{"key":"2025090109453561000_7.1.e001104.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2"},{"key":"2025090109453561000_7.1.e001104.8","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-2-209"},{"key":"2025090109453561000_7.1.e001104.9","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911423031"},{"key":"2025090109453561000_7.1.e001104.10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/APO.0000000000000291","article-title":"Emerging therapies in neovascular age-related macular degeneration in 2020","volume":"9","author":"Samanta","year":"2020","journal-title":"Asia Pac J Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042760"},{"key":"2025090109453561000_7.1.e001104.12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options","volume":"16","author":"Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062655"},{"key":"2025090109453561000_7.1.e001104.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2025090109453561000_7.1.e001104.15","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0000000000001142","article-title":"Metaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"2025090109453561000_7.1.e001104.16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/ceo.13949","article-title":"Neovascular age-related macular degeneration: a review of findings from the real-world fight retinal blindness! registry","volume":"49","author":"Nguyen","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.17","first-page":"514","article-title":"New treatment modalities for neovascular age-related macular degeneration","volume":"6","author":"Schlottmann","year":"2017","journal-title":"Asia Pac J Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society","volume":"10","author":"Chaikitmongkol","year":"2021","journal-title":"Asia Pac J Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","article-title":"Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service","volume":"33","author":"Gale","year":"2019","journal-title":"Eye"},{"key":"2025090109453561000_7.1.e001104.20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020325","article-title":"Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression","volume":"11","author":"Veritti","year":"2022","journal-title":"J Clin Med"},{"key":"2025090109453561000_7.1.e001104.21","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the trend study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"2025090109453561000_7.1.e001104.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2019-000398","article-title":"Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review","volume":"4","author":"Khanna","year":"2019","journal-title":"BMJ Open Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s12325-017-0483-1","article-title":"A retrospective study of ranibizumab treatment regimens for neovascular age-related macular degeneration (nAMD) in Australia and the United Kingdom","volume":"34","author":"Johnston","year":"2017","journal-title":"Adv Ther"},{"key":"2025090109453561000_7.1.e001104.24","doi-asserted-by":"publisher","DOI":"10.1159\/000502747"},{"key":"2025090109453561000_7.1.e001104.25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or Nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"2025090109453561000_7.1.e001104.26","doi-asserted-by":"crossref","DOI":"10.3390\/vision3030041","article-title":"Treat and extend treatment interval patterns with anti-VEGF therapy in nAMD patients","volume":"3","author":"Skelly","year":"2019","journal-title":"Vision"},{"key":"2025090109453561000_7.1.e001104.27","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of Treat-and-Extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"2025090109453561000_7.1.e001104.28","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2015.06.023","article-title":"Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study","volume":"160","author":"Prenner","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/ICU.0000000000000851","article-title":"Development of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"33","author":"Adamis","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"2025090109453561000_7.1.e001104.31","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.oret.2020.11.004","article-title":"End-of-study results for the ladder phase 2 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"5","author":"Khanani","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"2025090109453561000_7.1.e001104.32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jconrel.2022.03.005","article-title":"In-Vitro characterization of ranibizumab release from the Port delivery system","volume":"345","author":"Yohe","year":"2022","journal-title":"J Control Release"},{"key":"2025090109453561000_7.1.e001104.33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3928\/23258160-20220408-01","article-title":"Implant insertion procedure of the Port delivery system with ranibizumab: overview and clinical pearls","volume":"53","author":"Pieramici","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2025090109453561000_7.1.e001104.34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"2025090109453561000_7.1.e001104.35","unstructured":"Extension study for the Port delivery system with ranibizumab (portal) (portal). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03683251"},{"key":"2025090109453561000_7.1.e001104.36","unstructured":"Susvimo . [package insert]. South San Francisco, CA Genentech, Inc; 2021."},{"key":"2025090109453561000_7.1.e001104.37","unstructured":"Eichenbaum D . \"Long-term (+ 3-Year) Safety and Efficacy Data for the Port Delivery System:Interim Analysis Results of the Portal Extension Study of the Port Delivery System With Ranibizumab (PDS) in Patients With Neovascular Age-Related Macular Degeneration (nAMD)\" Angiogenesis, Exudation, and Degeneration; 2022."},{"key":"2025090109453561000_7.1.e001104.38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2147\/OPTH.S194234","article-title":"Therapeutic potential of the ranibizumab port delivery system in the treatment of AMD: evidence to date","volume":"14","author":"Chen","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40123-017-0083-9","article-title":"A review of ranibizumab for the treatment of diabetic retinopathy","volume":"6","author":"Stewart","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"2025090109453561000_7.1.e001104.40","first-page":"251584142110726","article-title":"Ranibizumab port delivery system in neovascular age-related macular degeneration","volume":"14","author":"Chandrasekaran","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"2025090109453561000_7.1.e001104.41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40942-021-00325-5","article-title":"Pipeline therapies for neovascular age related macular degeneration","volume":"7","author":"Arepalli","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"2025090109453561000_7.1.e001104.42","unstructured":"A depot formulation of sunitinib malate (GB-102) compared to aflibercept in subjects with wet AMD (ALTISSIMO). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03953079"},{"key":"2025090109453561000_7.1.e001104.43","unstructured":"Chuidian M . \u201cUpdate on GB-102 for Neovascular Age-Related Macular Degeneration\u201d Clinical Trails at the Summit, 2022. Available: https:\/\/investors.graybug.vision\/static-files\/3323a8ed-30cc-48f1-ad4a-1dc451740305"},{"key":"2025090109453561000_7.1.e001104.44","unstructured":"First in human study to evaluate the safety and tolerability of EYP-1901 in patients with wet age related macular degeneration (wAMD). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04747197"},{"key":"2025090109453561000_7.1.e001104.45","unstructured":"EyePoint pharmaceuticals Announces updated positive interim safety and efficacy data from ongoing phase 1 DAVIO clinical trial evaluating EYP-1901 for the treatment of wet AMD. Available: https:\/\/www.prnewswire.com\/news-releases\/eyepoint-pharmaceuticals-announces-updated-positive-interim-safety-and-efficacy-data-from-ongoing-phase-1-davio-clinical-trial-evaluating-eyp-1901-for-the-treatment-of-wet-amd-301481159.html [Accessed 22 Aug 2022]."}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2022-001104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:45:47Z","timestamp":1756745147000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2022-001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,26]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjophth-2022-001104"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2022-001104","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}